Previous 10 | Next 10 |
Exelixis, Inc. (EXEL) Cowen 41st Annual Health Care Conference March 01, 2021 2:40 PM ET Company Participants Mike Morrissey – Chief Executive Officer Conference Call Participants Yaron Werber – Cowen Presentation Yaron Werber Good afternoon everybody and thank you once again fo...
– CHMP recommendation follows U.S. FDA approval of CABOMETYX in combination with OPDIVO in January – Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use...
Presentations to be webcast on www.exelixis.com Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in fireside chats at the following virtual investor conferences in ...
Exelixis (EXEL) announces that the U.S. FDA has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX) as a potential treatment for certain patients with differentiated thyroid cancer ((DTC)).The FDA’s Breakthrough Therapy Designation aims to expedite the development...
– U.S. FDA designation based on an interim analysis of the phase 3 COSMIC-311 pivotal trial, in which cabozantinib demonstrated significant improvement in progression-free survival – – Exelixis expects to submit supplementary New Drug App...
- Presentation to be webcast on www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer will participate in a fireside chat as part of the SVB Leerink 10 th Annual G...
After the market close on Friday, Exelixis, Inc (EXEL) announced final data for a phase 1 trial for cabozantinib in genitourinary (“GU”) tumors. The open-label, non-randomized trial was sponsored and conducted by the U.S. National Cancer Institute.A partnersh...
Exelixis, Inc (EXEL) has announced positive phase 2 results for CABOMETYX® (cabozantinib) in patients with metastatic papillary renal cell carcinoma (“PRCC”), a type of kidney cancer.The randomized phase 2 trial supported by the National Cancer Institute of Nation...
– Results of phase 2 trial show CABOMETYX significantly improved progression-free survival versus current guideline-preferred therapy – – Data to be presented during the 2021 American Society of Clinical Oncology’s Genitourinary Cancers Sympos...
– Study demonstrated objective response rates of 38% in all patients, 62.5% in patients with renal cell carcinoma and 42.4% in patients with urothelial carcinoma – – Data to be presented during the 2021 American Society of Clinical Oncology’s ...
News, Short Squeeze, Breakout and More Instantly...
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (Nasdaq: EXEL) announced today that its second quarter 2024 financial results will be released on Tuesday, August 6, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Ex...
2024-07-11 08:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...